Basel, 28 April 2021 - Roche today announced the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favour of maintaining accelerated approval of Tecentriq (atezolizumab) for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC, bladder cancer) who are not eligible fo

Basel, 22 April 2021 - Roche and GenMark Diagnostics, Inc. today announced that Roche's wholly owned subsidiary Geronimo Acquisition Corp. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of GenMark Diagnostics, Inc.

The Elecsys EBV panel accurately identifies the EBV infection stage from a single blood sample, which means less confirmatory testing and, potentially, faster diagnosis for patients Clear and quick diagnosis of acute infection allows physicians to decide faster on treatment for transplant patients The EBV panel can be used to rule out other acut

Basel, 25 March 2021 - Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of GenMark Diagnostics, Inc. (NASDAQ: GNMK) at a price of $24.05 per share.

The REMDACTA clinical trial of Actemra/RoActemra plus Veklury did not meet its primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia or its key secondary endpoints compared to Veklury alone Roche will submit the REMDACTA results to a peer-reviewed journal - Basel, 11 March 2021 - Roche today announce

About 90,000 women globally die from endometrial cancer each year 1 VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI (dostarlimab-gxly ) Roche/GSK collaboration represents an important step towards a personalised healthcare strategy that can help

More than twice as many babies (61% vs.

Evrysdi has proven efficacy in adults, children and babies two months and older, as shown in two pivotal clinical trials Roche is actively engaging with health authorities in the EU to achieve broad and rapid access for people with SMA More than 3,000 patients now treated with Evrysdi in clinical trial, compassionate use and real-world settings

Roche to acquire GenMark Diagnostics for US$ 24.05 per share with the expectation to close in the 2nd quarter of 2021 GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sample GenMark's ePlex platform delivers rapid and actionable results so clinicians can determine the cause of infection and the most effective treatment, potentially saving lives and alleviating the healthcare burden.

For patients living in areas with limited healthcare resources, WHO prequalification ensures access to the highest quality diagnostics Access to broader reliable diagnostic solutions helps healthcare communities working to expedite and increase disease elimination programs Roche's Global Access Program provides innovative diagnostic solutions im